Bionano Genomics, Inc. (BNGO)
BNGO Stock Price Chart
Explore Bionano Genomics, Inc. interactive price chart. Choose custom timeframes to analyze BNGO price movements and trends.
BNGO Company Profile
Discover essential business fundamentals and corporate details for Bionano Genomics, Inc. (BNGO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Diagnostics & Research
IPO Date
21 Aug 2018
Employees
98.00
Website
https://www.bionanogenomics.comCEO
Robert Erik Holmlin
Description
Bionano Genomics, Inc. focuses on providing advanced solutions for analyzing genomes. The company's flagship offering is Saphyr, a complete system that processes samples to results, enabling the analysis of structural variations in the genome using optical genome mapping. This technology is vital for deciphering genetic variations and their functional roles. The Saphyr platform includes the Saphyr instrument, a device capable of imaging single molecules; the Saphyr Chip, a disposable component equipped with nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide essential reagents and protocols for extracting and tagging ultra-high molecular weight DNA. Furthermore, Bionano Genomics supplies Saphyr and Bionano compute servers to support its analytical operations. It also offers NxClinical, a single software system designed for the analysis and interpretation of genomic variants identified through microarray and next-generation sequencing data, serving both cytogenetics and molecular genetics applications. In addition to its product line, Bionano Genomics delivers a variety of specialized testing and laboratory services. These include: FirstStepDx PLUS: A chromosomal microarray service used to identify underlying genetic causes in individuals with autism spectrum disorder, developmental delay, and intellectual disability. Fragile X syndrome (FXS) testing services: Comprehensive diagnostic testing for FXS. NextStepDx PLUS: An exome sequencing test aimed at detecting genetic variants associated with childhood developmental disorders. EpiPanelDx PLUS: A genetic testing panel for patients experiencing seizures, infantile spasms, encephalopathy, or febrile seizures. PGx test: A pharmacogenomics test that identifies over 60 alleles across 11 genes relevant to drug response. Bionano Genomics was founded in 2003 and operates from its corporate headquarters in San Diego, California.
BNGO Financial Timeline
Browse a chronological timeline of Bionano Genomics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 Aug 2026
EPS estimate is -$0.70, while revenue estimate is $7.48m.
Earnings released on 13 May 2026
EPS came in at -$0.76 surpassing the estimated -$0.81 by +6.17%, while revenue for the quarter reached $6.69m , beating expectations by +1.82%.
Earnings released on 23 Mar 2026
EPS came in at -$0.03 surpassing the estimated -$0.81 by +96.30%, while revenue for the quarter reached $7.95m , beating expectations by +0.91%.
Earnings released on 13 Nov 2025
EPS came in at -$1.59 surpassing the estimated -$1.81 by +12.15%, while revenue for the quarter reached $7.37m , missing expectations by -6.75%.
Earnings released on 14 Aug 2025
EPS came in at -$1.99 surpassing the estimated -$2.69 by +26.02%, while revenue for the quarter reached $6.73m , missing expectations by -6.78%.
Earnings released on 14 May 2025
EPS came in at -$1.15 surpassing the estimated -$3.49 by +67.05%, while revenue for the quarter reached $6.46m , beating expectations by +3.31%.
Earnings released on 31 Mar 2025
EPS came in at -$57.49 falling short of the estimated -$6.00 by -858.17%, while revenue for the quarter reached $8.16m , beating expectations by +31.66%.
Stock split effective on 27 Jan 2025
Shares were split 1 : 60 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 Nov 2024
EPS came in at -$19.16 falling short of the estimated -$0.21 by -9.02k%, while revenue for the quarter reached $6.07m , missing expectations by -3.60%.
Earnings released on 7 Aug 2024
EPS came in at -$14.37 falling short of the estimated -$0.42 by -3.32k%, while revenue for the quarter reached $7.77m , beating expectations by +23.35%.
Earnings released on 8 May 2024
EPS came in at -$35.93 falling short of the estimated -$0.64 by -5.51k%, while revenue for the quarter reached $8.77m , missing expectations by -18.21%.
Earnings released on 5 Mar 2024
EPS came in at -$57.49 falling short of the estimated -$0.87 by -6.51k%, while revenue for the quarter reached $10.72m , beating expectations by +1.33%.
Earnings released on 8 Nov 2023
EPS came in at -$88.62 falling short of the estimated -$44.91 by -97.33%, while revenue for the quarter reached $9.32m , missing expectations by -11.59%.
Earnings released on 9 Aug 2023
EPS came in at -$74.25 falling short of the estimated -$53.89 by -37.78%, while revenue for the quarter reached $8.66m , beating expectations by +4.49%.
Stock split effective on 7 Aug 2023
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 9 May 2023
EPS came in at -$71.86 falling short of the estimated -$53.89 by -33.35%, while revenue for the quarter reached $7.42m , beating expectations by +0.75%.
Earnings released on 9 Mar 2023
EPS came in at -$77.84 falling short of the estimated -$53.89 by -44.44%, while revenue for the quarter reached $8.22m , beating expectations by +2.69%.
Earnings released on 3 Nov 2022
EPS came in at -$65.87 surpassing the estimated -$71.86 by +8.34%, while revenue for the quarter reached $7.22m , beating expectations by +6.28%.
Earnings released on 4 Aug 2022
EPS came in at -$65.87 falling short of the estimated -$59.88 by -10.00%, while revenue for the quarter reached $6.67m , beating expectations by +6.16%.
Earnings released on 5 May 2022
EPS came in at -$65.87 falling short of the estimated -$47.90 by -37.52%, while revenue for the quarter reached $5.70m , missing expectations by -0.12%.
Earnings released on 1 Mar 2022
EPS came in at -$47.90 falling short of the estimated -$41.92 by -14.27%, while revenue for the quarter reached $6.30m , beating expectations by +13.09%.
Earnings released on 4 Nov 2021
EPS came in at -$41.92 falling short of the estimated -$35.93 by -16.67%, while revenue for the quarter reached $4.66m , beating expectations by +10.05%.
Earnings released on 4 Aug 2021
EPS came in at -$35.93 falling short of the estimated -$29.94 by -20.01%, while revenue for the quarter reached $3.86m , meeting expectations.
BNGO Stock Performance
Access detailed BNGO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
